FinanceFinancial Post1 day ago
PharmaEssentia Buys Canadian Partner FORUS for $36.5M
1 min read
PharmaEssentia acquired FORUS Therapeutics for US$36.5 million, deepening its Canadian hematology-oncology presence. FORUS submitted a New Drug Submission for BESREMi in polycythemia vera in July 2025, with regulatory approval expected in Q3 2026. The deal fully integrates Canadian regulatory, medical, and commercial resources.
Level
Hype check
Tap to vote and see what everyone thinks.
